Workshop series to identify, discuss, and develop recommendations for the optimal generation and use of in vitro assay data for tobacco product regulation
Ended Project Grant Awarded Last action
- Award ID
- R13FD007386
- Recipient
-
Institute For In Vitro Sciences, Inc. UEI YBLAQDKBY5P6
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $99,528
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding
-
- $49,669.34 Federal
- $49,859.00 Non-federal
- Funding agency
- Center for Tobacco Products Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Description
- Abstract
- Research priorities for the center for tobacco products (CTP) include "toxicological assays (in vivo and in vitro) to compare toxicity across different types of tobacco products within the same class, including electronic nicotine delivery systems (ends), cigars, waterpipes, and smokeless tobacco." although CTP regulatory guidance documents include genotoxicity and other in vitro assays in the types of toxicity information required for submissions, there is no standardized guidance or regulatory approved methods for the evaluation of various tobacco products, including ends. Therefore, the institute for in vitro sciences (iivs), a 501(c)(3) nonprofit organization, has organized a workshop series to identify, discuss and develop recommendations for the best scientific/technical approaches for generating and interpreting in vitro assay data for comparing toxicity within and across tobacco product classes. Designed as true working meetings, expert stakeholders will discuss and develop recommendations that will then be published. The initial focus of the series has been on the regulatory genetic toxicology assays (ames test, in vitro mammalian assays for cytogenetic damage and gene mutation). Going forward there will be an increasing emphasis on human disease models. These workshops provide a unique opportunity for multiple stakeholders to share their expertise and will provide published resources that regulatory agencies, academic laboratories, and industry may use as they address the public health issues related to the use of tobacco products. Some of workshop reports may serve as authoritative publications that can be referenced for optimal methodologies and data interpretation. So far, the workshops have identified important issues for using in vitro assays for evaluating tobacco products, and have focused on several of CTP's high-priority topics. Multiple working groups have been established to collect background information, to hold discussions between workshops, to draft manuscripts, and to develop recommendations that are presented and discussed during the workshops. Consensus statements have resulted from these workshops. Two manuscripts have been published and two are in preparation. For upcoming workshops additional background documents are in preparation by working groups. Methods for generating aerosols for in vitro cell exposure and quantitative approaches to comparing toxicity potency will be the focus of a virtual workshop in april 2021. Workshops for october 2021 and april 2022 are now planned. Working groups are discussing and preparing background manuscripts with a focus on ends products and, in addition, (1) methods for dosimetry, (2) recommendations for the ames test, and (3) recommendations for the mouse lymphoma gene mutation assay. Also included will be approaches for evaluating both general toxicity and disease-causing potential of tobacco products using 3-d respiratory models,
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$190 | $0 | |
| Amendment | -$49,859 | $0 | |
| Amendment | $49,859 | $0 | |
| Original award | $49,859 | $49,859 |
Quick answers
Who received award R13FD007386?
R13FD007386 was awarded to Institute For In Vitro Sciences, Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on August 1, 2021.
How much is award R13FD007386 worth?
$99,528 has been obligated on R13FD007386: $49,669 in federal funding and $49,859 in non-federal funding.
Which agency awarded R13FD007386?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R13FD007386, with funding from Center for Tobacco Products (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award